专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07727994B2 Methods of treating patients suffering from movement disorders 有权
标题翻译：治疗运动障碍患者的方法
公开(公告)号：US07727994B2
公开(公告)日：2010-06-01
申请号：US11326516
申请日：2006-01-06
申请人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
发明人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
IPC分类号： A61K31/522 , A61K31/505
CPC分类号： A61K31/522 , A61K9/0019 , A61K9/20 , A61K9/48 , A61K31/198 , A61K45/06
摘要： The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
摘要翻译：本发明涉及通过向有需要的患者施用有效量的一种或多种腺苷A 2A受体拮抗剂来治疗运动障碍的方法。本发明还提供降低L-DOPA在接受L-DOPA治疗的帕金森病治疗中的不良反应的方法。本发明进一步提供了通过将L-DOPA治疗与有效量的一种或多种腺苷A 2A受体拮抗剂组合（即L-DOPA备用效应）来治疗具有亚临床有效剂量的L-DOPA的帕金森病患者的方法和组合物，。本发明还提供了通过共同施用至少一种腺苷A 2A受体拮抗剂，L-DOPA和多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂来有效治疗帕金森病的方法。本发明还提供了延长帕金森病有效治疗的方法，通过单独或与多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂一起施用腺苷A2A受体拮抗剂，而无需先前或随后给予L-DOPA ，延迟或消除L-DOPA电机并发症。

2. 发明申请

US20120122897A1 METHODS OF TREATING PATIENTS SUFFERING FROM MOVEMENT DISORDERS 审中-公开
标题翻译：治疗运动障碍患者的方法
公开(公告)号：US20120122897A1
公开(公告)日：2012-05-17
申请号：US13297341
申请日：2011-11-16
申请人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
发明人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
IPC分类号： A61K31/522 , A61P25/00 , A61P25/14 , A61P25/16
CPC分类号： A61K31/522 , A61K9/0019 , A61K9/20 , A61K9/48 , A61K31/198 , A61K45/06
摘要： Methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof and methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. Also, methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA with an effective amount of one or more adenosine A2A receptor antagonists, optionally with a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.
摘要翻译：通过向有需要的患者施用有效量的一种或多种腺苷A2A受体拮抗剂和降低L-DOPA在接受L-DOPA治疗帕金森病的患者中的不利影响的方法来治疗运动障碍的方法。此外，用有效量的一种或多种腺苷A2A受体拮抗剂，任选地与多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂治疗具有亚临床有效剂量的L-DOPA的帕金森病患者的方法和组合物。

3. 发明申请

US20060178379A1 Methods of treating patients suffering from movement disorders 有权
公开(公告)号：US20060178379A1
公开(公告)日：2006-08-10
申请号：US11326414
申请日：2006-01-06
申请人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
发明人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
IPC分类号： A61K31/522 , A61K31/198 , A61K31/137
CPC分类号： A61K31/522 , A61K9/0019 , A61K9/20 , A61K9/48 , A61K31/198 , A61K45/06
摘要： The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.

4. 发明授权

US07727993B2 Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy 有权
标题翻译：管理腺苷A2A受体拮抗剂以减少或抑制帕金森病治疗的副作用
公开(公告)号：US07727993B2
公开(公告)日：2010-06-01
申请号：US11326414
申请日：2006-01-06
申请人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
发明人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
IPC分类号： A61K31/522 , A61K31/505
CPC分类号： A61K31/522 , A61K9/0019 , A61K9/20 , A61K9/48 , A61K31/198 , A61K45/06
摘要： The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
摘要翻译：本发明涉及通过向有需要的患者施用有效量的一种或多种腺苷A 2A受体拮抗剂来治疗运动障碍的方法。本发明还提供降低L-DOPA在接受L-DOPA治疗的帕金森病治疗中的不良反应的方法。本发明进一步提供了通过将L-DOPA治疗与有效量的一种或多种腺苷A 2A受体拮抗剂组合（即L-DOPA备用效应）来治疗具有亚临床有效剂量的L-DOPA的帕金森病患者的方法和组合物，。本发明还提供了通过共同施用至少一种腺苷A 2A受体拮抗剂，L-DOPA和多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂来有效治疗帕金森病的方法。本发明还提供了延长帕金森病有效治疗的方法，通过单独或与多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂一起施用腺苷A2A受体拮抗剂，而无需先前或随后给予L-DOPA ，延迟或消除L-DOPA电机并发症。

5. 发明申请

US20060148827A1 Methods of treating patients suffering from movement disorders 有权
标题翻译：治疗运动障碍患者的方法
公开(公告)号：US20060148827A1
公开(公告)日：2006-07-06
申请号：US11326516
申请日：2006-01-06
申请人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
发明人： Hiroshi Kase , Akihisa Mori , Yutaka Waki , Yutaka Ohsawa , Akira Karasawa , Yoshihisa Kuwana
IPC分类号： A61K31/522 , A61K31/198 , A61K31/137
CPC分类号： A61K31/522 , A61K9/0019 , A61K9/20 , A61K9/48 , A61K31/198 , A61K45/06
摘要： The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
摘要翻译：本发明涉及通过向有需要的患者施用有效量的一种或多种腺苷A 2A 2受体拮抗剂来治疗运动障碍的方法。本发明还提供降低L-DOPA在接受L-DOPA治疗的帕金森病治疗中的不良反应的方法。本发明进一步提供了通过将L-DOPA治疗与有效量的一种或多种腺苷A 2A受体拮抗剂组合（用于治疗患有亚临床有效剂量的L-DOPA）的帕金森病患者的方法和组合物即L-DOPA保护作用）。本发明还提供了通过共同施用至少一种腺苷A 2A受体拮抗剂，L-DOPA和多巴胺激动剂和/或COMT抑制剂和/或MAO来有效治疗帕金森病的方法抑制剂。本发明还提供了通过单独或与多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂一起施用腺苷A 2A受体拮抗剂而延长帕金森病有效治疗的方法，而没有之前或之后的L-DOPA给药，延迟或去除L-DOPA运动并发症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式